R 142440

Drug Profile

R 142440

Latest Information Update: 13 May 2008

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class
  • Mechanism of Action Osteoprotegerin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 07 Apr 2006 Preclinical trials in Osteoporosis in USA (Injection)
  • 07 Apr 2006 Preclinical trials in Osteoporosis in Europe (Injection)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top